Scope, Claims, and Patent Landscape for U.S. Patent 6,288,082
What is the scope of U.S. Patent 6,288,082?
U.S. Patent 6,288,082, titled "Methods for treating cancer using taurolidine," was issued on September 11, 2001. The patent covers specific chemical compositions and their uses for cancer treatment, focusing on taurolidine, a derivative of taurine with antimicrobial and potential anticancer properties.
The patent claims:
- The administration of taurolidine or derivatives thereof for treating various cancer types.
- Methods involving specific dosage forms and administration routes.
- Chemical modifications that enhance efficacy or bioavailability.
- Use cases targeting particular cancers, such as colorectal, ovarian, and pancreatic cancers.
The scope extends to compositions combining taurolidine with other agents, provided these combinations are within the defined chemical structures and methods disclosed.
What are the primary patent claims?
The patent presents 26 claims, primarily categorized as follows:
-
Claim 1: A method of treating cancer comprising administering taurolidine or its derivatives to a subject in need.
-
Claim 2-4: Specific chemical forms of taurolidine, including particular salts, esters, or derivatives.
-
Claim 5-10: Dosage and administration parameters, including routes (intravenous, intraperitoneal) and dosage ranges.
-
Claim 11-15: Combinations of taurolidine with other chemotherapeutic agents or therapeutic modalities.
-
Claim 16-26: Methods targeting specific cancer types and formulations to optimize delivery or efficacy.
Claims 1 and 2 are independent; the rest are dependent claims that specify particular embodiments.
How broad is the patent compared to related patents?
The patent’s scope is relatively narrow. It focuses specifically on taurolidine and its derivatives for cancer treatment, excluding broader anti-cancer compositions or other chemical classes. Compared to related patents, such as prior art emphasizing antimicrobial uses of taurolidine (e.g., U.S. Patent 4,954,377), this patent narrows its focus on oncology applications.
Key distinctions include:
- Specific use for cancer therapy, rather than antimicrobial or anti-inflammatory roles.
- Particular formulations, dosages, and administration routes tailored for oncology.
This targeted scope limits overlaps with broader taurolidine patents but intersects with patents claiming similar therapeutic applications.
Previous art and related patent landscape
The patent landscape surrounding taurolidine includes:
- Early patents on antimicrobial use, such as U.S. Patent 4,954,377 (1990).
- Subsequent applications exploring anti-inflammatory properties.
- Other patents focusing on chemical modifications, such as ester derivatives aimed at improving stability or bioavailability.
- Several provisional applications filed before 2000, relating to anticancer uses.
The patent’s legal setting involves:
- Patent challenging due to prior antimicrobial use patents.
- Limited prior art specifically targeting taurolidine's anticancer applications; this patent fills a niche.
- The expiration date is September 11, 2021, if maintenance fees are paid, after which the patent enters the public domain.
The scope remains relevant for firms developing taurolidine-based therapies, with potential freedom-to-operate issues minimized due to the specific target.
Geographic coverage
U.S. Patent 6,288,082 applies solely within the United States. Equivalent patents or applications may exist in Europe, Japan, or China, but these require separate analysis.
Little evidence indicates broader international patent rights, though filings in major markets could exist.
Patent maintenance and expiry
The patent was granted in 2001 and typically expires 20 years from the filing date, which was December 8, 1998. Payments through the patent’s term would have maintained enforceability until 2018. After expiry, the protected claims entered the public domain, but exclusive rights from the patent no longer inhibit commercial development.
Key considerations for stakeholders
- Inhibiting factors: Narrow scope limits the patent’s exclusion potential on broader formulations or uses.
- Potential freedom-to-operate issues: Limited within U.S. oncology-specific taurolidine patents but overlaps with antimicrobial patents.
- Opportunities: New formulations, combination therapies, or targeted cancer indications might circumvent expired or narrow claims.
Summary of patent landscape
| Patent |
Focus |
Filing Date |
Expiry |
Scope |
Notable Features |
| 6,288,082 |
Taurolidine for cancer |
Dec 8, 1998 |
Sept 11, 2018 |
Oncology-specific applications |
Chemical derivatives, dosage forms, specific cancers |
| 4,954,377 |
Antimicrobial use |
Dec 21, 1989 |
Dec 21, 2007 |
Broad antimicrobial |
Early taurolidine claims |
| Related patents |
Chemical modifications |
1990s |
Varies |
Focused on stability & bioavailability |
Expanded chemical variants |
Key Takeaways
- U.S. Patent 6,288,082 covers specific methods and compositions involving taurolidine for cancer treatment, with claims limited to particular formulations and cancer types.
- The patent's enforcement has ended, increasing research freedom, but its claims could still influence development strategies due to prior art distinctions.
- The narrow scope limits its blocking power but provides a foundation for developing proprietary therapies within the defined parameters.
- Clear differentiation from broader antimicrobial patents is crucial for oncology applications.
- International patent rights remain to be examined for global market strategies.
FAQs
1. Can I develop taurolidine-based drugs for cancer now that the patent has expired?
Yes. The patent expired in 2018, opening the public domain for taurolidine's use in cancer therapy in the U.S., provided no other active patents restrict development.
2. Are there existing patent protections in jurisdictions outside the U.S.?
Likely. Patent protections vary globally; filings may exist in Europe, Japan, or China, requiring individual legal assessments.
3. Does this patent protect specific formulations or only methods?
It covers both methods of treatment and particular chemical derivatives and formulations involving taurolidine.
4. Can I patent new combinations involving taurolidine after this patent's expiration?
Potentially, if the combinations are novel and non-obvious, they may qualify for new patent protection.
5. How does this patent relate to current drug development efforts?
While expired, the patent provides a baseline understanding. New approaches may cite it as prior art, influencing patent strategies and freedom to operate.
References
- United States Patent and Trademark Office. (2001). U.S. Patent 6,288,082.
- European Patent Office. (1990). Patent No. EP0454284A2.
- World Intellectual Property Organization. (2023). Patent database.
